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Patients with a chronic coronaff occlusion often undergo 
coronary angiography after weeks to months of occlusion. The 
published reports underestimate the extent of this problem be- 
cause such patients are often arbitrarily assigned to receive 
medical therapy or undergo bypass urgery as a result of poor 
success with percutaneous revascularization and substantial re- 
stenosis. Thus, there is controversy about he role of angioplasty 
in this patient cohort. The goal of this overview as to evaluate the 
available information about angioplasty in chronic coronary 
occlusions. The primary indication for attempted recanalization 
of a chronic coronary occlusion has been symptomatic angina 
pectoris. Anginal status often improves after successful proce- 
dures (70% vs. 31% with a failed procedure); left ventricular 
function may improve; and subsequent referral for coronary 
artery bypass graft surgery is uncommon (3% vs. 28% in unsuc- 
cessful cases). Successful recanalization is achieved in ~65% of 
attempted procedures. Inability to cross the stenosis with a guide 
wire is the most common cause of procedural failure. Statistically 
significant predictors of procedural success include older occlu- 
sions (75% <3 months old vs. 37% >3 months old), absence of any 
anterograde flow through the occlusion (76% with vs. 58% with- 
out), angiographically abrupt-appearing occlusions (50% vs. 77% 
with tapered occlusions), presence of bridging collateral vessels 
t23% with vs. 71% without) and lesions >15 mm. Procedural 
complications occur at a slightly lower incidence than in angio- 
plasty of high grade subtotal stenoses. Long-term success is 
limited, and restenosis can be expected in >50% of the patients. 
The experience with chronic total occlusions of saphenous vein 
bypass grafts is small, but there appear to be limited procedural 
success and significant procedural complications, particularly 
associated with distal emboli. The role of new pharmacologic 
agents has yet to be defined and that of new devices has been 
disappointing so far, but further technologic advances are on the 
horizon. 
(J Am Coil Cardiol 1995;26:1-11) 
Percutaneous transluminal coronary angioplasty has become a
well accepted therapy in the treatment of corona~ artery 
disease and exceeds the annual volume of coronary, artery 
bypass graft surgery. Even though chronic coronaw occlusions 
account for ~ 10% of coronary angioplasty procedures in most 
major centers, they continuc to be considered a leading 
contraindication to angioplasty. Although many reports deal- 
ing with chronic total occlusions have been published, the vast 
majority have been limited by small patient numbers, leaving 
all available studies of clinical outcome or prognostic harac- 
teristics ubstantially underpowcred. In an efl'ort to provide a 
broader perspective, we chose to use quantitative methods of 
combining information across studies. This approach is less 
than ideal because the studies often involve patients with 
different and sometimes incompletely characterized baseline 
qualities exposed to different reatment protocols. However, in 
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the absence of definitive studies we believe that this systematic 
overview clarifies relations that are not readily apparent from 
individual studies. 
Background and  Def in i t ions  
The earliest study of coronary occlusion angioplasty was by 
Savage t al. (1) in 1982 and reported results in 39 patients who 
had progressed from high grade stenosis at diagnostic angiog- 
raphy to total occlusion at angioplasty. Procedural success was 
achieved in 67% of these patients, and restenosis was reported 
in 27%. This early investigation suggested that coronary an- 
gioplasty of selected occlusions was feasible, with long term 
outcomes similar to those achieved in other patients undergo- 
ing this procedure. Subsequent studies of angioplasty of 
chronic occlusions reported lower procedural success and 
higher restenosis rates. In addition to less favorable clinical 
outcomes, angioplasty of chronic occlusions has been associ- 
ated with increased cost, increased catheterization laboratory 
time and equipment use and longer radiation exposure than 
angioplasty of high grade stenoses (2,3). 
The actual number of patients with coronary occlusions is 
not accurately represented by the published reports or by the 
~'; 1995 by the American C~llcge ~[' ('m diolog} 0735-1097/95/$9.50 
[1735-1097195)110156-X 
2 PUMA ET AL. JACC Vol. 26, No. t 
REVASCULARIZATION OF CHRONIC CORONARY OCCLUSIONS July 1995:1-11 
number of patients referred for angioplasty because many such 
patients are treated medically or with coronary artery bypass 
graft surgery. This underrepresentation was highlighted in the 
Bypass Angioplasty Revascularization I vestigation, where a 
chronic occlusion in a major vessel requiring revascularization 
was an exclusion criterion (4). Although the term coronary 
"occlusion" implies complete obstruction, it has been used 
arbitrarily in published reports (5) to represent both absolute 
occlusions (Thrombolysis nMyocardial Infarction [TIMI] flow 
grade 0) and "functional" occlusions (TIMI flow grade 1). 
Defining a coronary occlusion using a clinical estimate of its 
duration is also somewhat arbitrary and evolved from the 
expected pharmacologic restoration ofanterograde flow in the 
acute phases of a myocardial infarction. It seems reasonable to 
categorize occlusions <12 h old as acute, ->12 h and <1 month 
old as subacute, -> 1 month and <3 months old as early' chronic 
and ->3 months old as late chronic. 
There are no controlled studies of survival or symptom 
relief that compare different management options in patients 
with a chronic total occlusion. Information to support manage- 
ment decisions in this cohort of patients i  limited to observa- 
tional data and anecdotal experience. Currently available 
observational studies are limited by the absence of concurrent 
nonrandomized control subjects with careful documentation f 
confounding baseline characteristics. Interpretation of the 
outcomes may be somewhat clouded by the absence of objec- 
tive evaluations extending beyond the practitioners who per- 
formed the procedures. Despite these drawbacks, available 
studies are useful to develop hypotheses (which may bc 
evaluated in a prospective or randomized manner in the 
future). 
Histologic and Pathophysiologic Findings 
Total coronary occlusions comprise atherosclerotic plaques 
with thrombus formation that can vary by size, age and 
occlusiveness (6). These plaques develop after endothelial 
injury, which initiates interactions among platelets, fibrin and 
the arterial wall. This is followed by smooth muscle prolifera- 
tion, lipid deposition and accumulation, fibrosis, thrombosis 
(repeat injury repair process), ulceration and calcification (7). 
Thrombus formation can result in single or multiple layers of 
clot. These layers are likely to be secondary to previous plaque 
fissuring with subsequent thrombus formation. The last throm- 
bus to occur is probably the layer that causes the occlusion and 
the layer through which recanalization occurs. Fresh clot may 
allow a higher procedural success rate but also a higher 
complication rate, whereas older and more fibrosed clot may 
be associated with a lower probability of recanalization (8,9). 
In the absence of obvious thrombus, total occlusions may have 
a similar angiographic appearance regardless of age and 
underlying pathology. However, visual determination f the 
presence or absence of thrombus was not shown to be sensitive 
or specific by pathologic inspection in the Coronary Angio- 
plasty Versus Excisional Atherectomy Trial (10). A recent 
autopsy study (11) correlating histologic and angiographic 
findings in patients with chronic occlusions found that anglo- 
graphic variables of tapering with short occluded segments may 
be favorable for coronary angioplasty because of the presence 
of a small lumen of loose fibrous tissue penetrating the 
occluded segment. 
Complete occlusion of a vein graft within the first month 
after operation isprimarily due to thrombus inassociation with 
adverse technical factors, such as anastomotic narrowing, 
trauma to the vein graft or inadequate distal runoff. The 
thrombus can be localized or diffuse within the vein graft. 
Intimal proliferation with superimposed thrombus becomes a
more important cause of occlusion between the 1st and 12th 
month. The intima becomes an admixture of smooth muscle 
cells, fibroblasts, collagen and ground substance, whereas the 
media undergoes atrophy and fibrosis. Beyond the first year 
after grafting, atherosclerosis becomes more significant in the 
pathogenesis of vein graft occlusion. Atherosclerotic plaques 
in vein grafts, like those found in native coronary arteries, tend 
to be rich in cholesterol, necrotic debris, blood elements and 
foam cells (12). 
Impact of Revascularization 
Survival outcome. The theoretic rationale for revascular- 
ization of a chronic total coronary occlusion is extrapolated 
from the acute myocardial infarction experience. In patients 
presenting with an acute occlusion and myocardial infarction, 
restoration of anterograde flow with thrombolytic therapy has 
been shown (13-15) to improve in-hospital, 30-day and 1-year 
survival while preserving regional and global left ventricular 
function. Outcomes may be similar or better with a strategy of 
primary angioplasty in acute myocardial infarction (16). The 
mechanisms of mortality reduction have long been thought to 
be related to reduced infarct size and myocardial salvage. 
Several investigators (17,18) have offered other possible mech- 
anisms of benefit that include mechanical factors, such as 
improved healing (less expansion and aneurysm formation, 
lower wall stress and improved iastolic function), ascaffolding 
effect of the patent artery preventing rupture or an improved 
electrophysiologic substrate. 
It has recently been reported (19) that patients with a 
chronic total occlusion of a single vessel treated medically had 
a high mortality rate over long-term follow-up despite a low 
1-year mortality rate (25% at 10 years vs. 2% at 1 year). 
Similarly, a higher 2-year adjusted mortality rate in patients 
with a total occlusion than in those with subtotal occlusion has 
been reported (20). In a retrospective study (21), patients 
without anterograde flow in an infarct-related artery had a 
higher mortality rate than a contemporaneous group with 
anterograde flow (32% vs. 6%, respectively), which was further 
exacerbated in the subgroup with left ventricular ejection 
fraction <50% (49% vs. 9%, respectively). In patients with 
single-vessel disease followed up for a mean of 48 months by 
Trappe et al. (22), a total coronary occlusion was associated 
with a significantly higher incidence of sudden death (15%) 
than was a high grade stenosis (3%). 
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Table l. Relation Between Revascularization and Symptom Relief 
Successful Failed 
Follow-Up PTCA PTCA 
Study* (months) (no. of pts) (no. of pts) 
Holmes ct al. (36) 7 10/13 8/11 
Kcrciakes et al. (27) 7 3() 41! NR 
Serruys et al. (3(/) 7 18/28 Nt ~, 
DiSciascio et al. (35) 8 11~29 NR 
Melchior et al. (311 8 4049 NR 
Finci et al. (28) 24 57/11111 26/100 
Warren ct al. (34) 31 I6i20 NR 
Bell et al. (25) 32 178~234 NR 
Ruocco et al. (20) 24 I IlL 16(I NR 
Stewart ct al. (3) 14 31,45 NR 
Total 5tl6,718 34/111 
70'~ 3V:~ 
95% CI (~7 74~; 22 39% 
*Numbers in parentheses are reference numbcrs. (1 confidence interval: 
PTCA percutaneous transluminalcoronary ngioplasty; pts patients: NR 
not reported. 
Several investigators (23-25) have reported better survival 
in patients with successful coronary angioplasty of a chronic 
total occlusion than in those whose procedure failed. In 
addition, aretrospective analysis by Moliterno et al. (26) found 
survival markedly superior by mechanical restoration of an 
occluded infarct-related artery with coronary artery bypass 
graft surgery or coronary, angioplasty. Although these analyses 
suggest a benefit to restoration of anterograde flow, the 
possibiliW of harm done by the failed procedure cannot be 
excluded as the reason for the survival difference. 
Symptom relief. An average chronic total coronary occlu- 
sion with well developed collateral vessels is hemodynamically 
similar to a 90% coronary stenosis without collateral vessels 
(27). Therefore, although an acute infarction is rare in the 
follow-up of chronic occlusions, angina pectoris is a common 
symptom and represents the most common cause for at- 
tempted angioplasty. When successful, the majority of patients 
can expect a significant reduction or complete resolution o1 
symptoms. Kereiakes et al. (27) reportcd that 75% of patients 
with successful recanalization f a chronic occlusion were free 
of anginal symptoms at a mean foLlow-up of 7.3 months. In a 
comparison of 100 patients with a total occlusion and success- 
ful coronary angioplasty versus a similar group with unsuccess- 
ful angioplasty, a greater than 2:1 ratio of asymptomatic 
patients in the successful versus failed group was reported (23). 
These results have been supported by multiple studies 
(3,20,24,29,30,31), and several investigators have reported a
success rate >80% in asymptomatic patients. The point esti- 
mate of symptom relief is 70%, whereas failure is associated 
with only a 31% incidence of relief of symptoms (Table 1). 
Left ventricular function. Global and regional left ventric- 
ular function has been shown to improve in patients who have 
undergone successful coronary angioplasty of a chronic occlu- 
sion and remained free of restenosis (32). In patients with a 
previous infarction (2 days to 5 weeks), succcssful angioplasty 
Table 2. Relation Between Revascularization and Subsequent 
Coronary Arte~' Bypass Graft Surgery. 
Study* 
Failed Successful 
PTCA PTCA 
(no. of pts) (no. of pts) 
Hohnes ctal. (36) 8/11 1/13 
Scrruvs ct al. (30) l 1/21 3/28 
Melchior et al. (31) 2(I/44 2/49~ 
Finci et al. (28) 37/100 7/100 
Warren et al, (34) 7/18 3/26 
lvanhoc el al. (24) 33/148 10/332 
l lainc ctal. (14) 22/150 1/350 
I'otal 138/492 27/898 
285~ 3% 
<~5~; ('1 24-32~;'b 2-4% 
~Numbcrs in parentheses are reference numbers. #Seven initial successes 
lost to follow-up. Abbreviations as in Table 1. 
of an infarct-related artery resulted in an improved regional 
wall motion score (25 [78%] of 32) by contrast echocardiogra- 
phy compared with unsuccessful angioplasty (1 [11%] of 9), 
suggesting that myocardium can remain viable but nonfunc- 
tional for a prolonged time after an acute infarction (33). 
Subsequent coronary, artery bypass urgery. Several stud- 
ies (25,29,31,33) have suggested that the most important 
benefit derived from successful coronary angioplasty of a 
chronic total coronary occlusion may be that there is less need 
for subsequent coronary artery bypass urgery (Table 2). Bell 
et al. (25) analyzed the long-term follow-up of 354 patients 
undergoing angioplasty of a chronic occlusion. A~ 5 years, 
freedom from death, myocardial infarction, severe angina and 
coronary artery bypass graft surgery was 52% in the group with 
successful versus 17% in that with unsuccessful angioplasty 
(p < 0.001). Although 7-year cumulative survival was similar 
(82~{- vs. 75%, successful vs. failed), multivariable analysis 
revealed that successful angioplasty was the most significant 
predictor of freedom from coronary artery bypass graft sur- 
gery. This trend has been supported by several studies 
(14,24,34). 
The finding of less surgical intervention i patients with a 
successful coronary angioplasty procedure cannot be inter- 
preted definitively as indicating that the use of angioplasty in 
chronic occlusions reduces the need for bypass urgery com- 
pared with not attempting angioplasty. An alternative xpla- 
nation would be that once the clinician and the patient decide 
on an aggressive approach to therapy for this condition, failure 
of one method (angioplasty) leads to higher use of another 
approach (bypass urgery), regardless ofthe patient's symptom 
status. These alternative interpretations of the same data can 
only be resolved through carefully controlled observational 
studies that include patients with chronic occlusions and an 
initial treatment s rategy of medical therapy without attempted 
revascularization r, preferably, through prospective con- 
trolled clinical trials. 
Procedural success. In general, when a patient is brought 
to the laboratory for a planned angioplasty, it is counted as an 
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Table 3. Procedural Success 
Study Year No. of Pts No. of Lesions 
Clinical Success 
No. of Lesions % of Lesions 
Holmes et al. (36) 1984 24 24 
Kereiakes et al. (27) 1985 76 76 
Serruys et al. (30) 1985 49 49 
DiSciascio et al. (35) 1986 46 46 
Mclchior ct al. (31) 1987 100 100 
Safian et al. (29) 1988 271 271 
Ellis et al. (44) 1989 484 484 
Hamm et al. (37) 199(I 154 154 
Stone et al. (41) 1990 905 971 
Finci et al. (28) 199/} 21111 200 
Warren ct al. (34) 19911 44 44 
Ivanhoe et al. 124) 1992 480 48(1 
Bell et al. (25) 1992 354 363 
Ruocco ct al. (20) 1992 271 271 
Maicllo et al. (42) 1992 294 365 
Tan ct al. (38) 1993 312 312 
Haine et al. 114) 1993 500 500 
Stewart et al. (3) 1993 100 1(11/ 
Total 4,664 4,810 
95q~ CI 
13 54 
40 54 
28 57 
29 63 
56 56 
186 69 
257 53 
113 73 
701 72 
100 50 
26 59 
317 66 
251 69 
190 67 
244 67 
191 61 
350 70 
47 47 
3,139 65% 
64-67% 
*Numbers in parentheses are reference numbers. Abbreviations as in Table 1. 
attempted procedure in the published reports, regardless of 
outcome. The definition of procedural success in the studies 
reviewed ranged from a very liberal >20% reduction in 
coronary stenosis and symptomatic improvement to the more 
stringent <50% residual stenosis at the end of the procedure 
without major complications and with improvement of at least 
one Canadian Cardiovascular Society class or improvement in 
exercise treadmill test performance (29,35). Most investigators 
defined procedural success as <50% residual stenosis at the 
end of the procedure. 
In most studies of patients undergoing coronary angioplasty 
of chronic total occlusions before 1988 (23,30,35,36), proce- 
dural success ranged from 53% to 68% (Table 3). Since then, 
reports of procedural success >70% have become common 
(14,37,38). The reasons for this trend toward improved proce- 
dural success are unclear but may be related to increased 
operator experience, improved patient selection and improved 
equipment. Kelsey et al. (39) noted that increased operator 
experience and improved equipment were directly related to 
increased procedural success for coronary angioplasty of high 
grade stenoses. Jollis et al. (40) reviewed the Medicare Pro- 
vider Analysis and Review file and reported an inverse relation 
between operator volume and mortality in patients >64 years 
old undergoing coronary angioplasty. In a large study Stone et 
al. (41) reported an improvement in procedural success for 
chronic total occlusions based on an operator learning curve. 
This finding was confirmed in a study by Maiello et al. (42) of 
patients who underwent angioplasty of chronic occlusions 
between November 1986 and March 1990. In the first 6 months 
of that review, the procedural success was 41%, whereas in the 
last 6 months, it was 73% (p < 0.001). When the studies shown 
in Table 3 were placed in a regression model, a significant 
association was found between the year of the study and the 
procedural success rate (chi-square 10.06, p = 0.002). 
P red ic tors  o f  Success  
It may be useful to categorize lesion characteristics evalu- 
ated for their impact on procedural success as those unique to 
total occlusions and those common to all coronary stenoses. 
Variables unique to total occlusions. Age of occlusion. A 
strong predictor of procedural failure is the duration of 
occlusion, which is typically estimated from an index clinical 
event, such as a myocardial infarction or a change in anginal 
Table 4. Predictors of Success: Durat ion of  Occlusion 
Study* 
Occlusion -<3 mo Occlusion >3 mo 
(no. of PTCA (no. of PTCA 
successes/attempts) successes/attempts) 
Holmes el al. (36) 13/19 0/5 
DiSciascio et al. (35) 25/39 4/7 
Safian et al. (29) 62/97 40/72 
Hamm et al. (37) 79/97 33/57 
Stone et al. (41) 26/29 29/39 
Bell et al. (25) 222/318 29/45 
Maiello et aL (42) 132/150 49/'110 
Tan et al. (38) 64/87 14/194 
Total 623/836 198/529 
75% 37% 
95% Cl 72-77% 33-42% 
*Numbers in parentheses are reference numbers. Abbreviations as in Table 1. 
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Table 5. Predictors of Success: Antcrograde Flow 
Study* 
Present+ Absents 
(no. of PTCA (no. of PTCA 
successes/attempts) successes/attempts) 
Serruys et al. (30) 13/16 15/33 
DiSciascio et al. (35) 16/23 13/23 
Safian et al. (29) 81/102 86/169 
Stone et al. (4l) 35/42 46/92 
lvanhoe t al. (24) 90/115 84/141 
Maiello et al. (42) 78/113 171/252 
Total 313/411 415/710 
76%; 58c;~ 
95% CI 72-8/1% 55-62% 
*Numbers in parentheses arc reference numbers, tFunctional occlusion. SAb- 
solute occlusion. Abbreviations as in Table 1. 
pattern (Table 4). When such an estimation is impossible, 
duration of occlusion cannot be reliably predicted. In an early 
investigation (36), coronary occlusions estimated to be <12 
weeks old were successfully opened 68% of the time, whereas 
there were no successes in the patients whose occlusions were 
estimated to be >12 weeks old. In larger, more recent inves- 
tigations (25,41), coronary, occlusions whose duration was 
estimated to be <3 months old were reported to be success- 
fully dilated 89% (p < 0.001) and 74% (p < 0.02) of the time. 
When the occlusions were estimated to be >3 months old, 
successful dilatation was achieved in 45% (p < 0.001) and 59% 
(p < 0.02), respectively. The inverse relation of duration of 
occlusion and procedural success has been supported by the 
results of other studies (14,20,28,31,35,38). These findings 
point to duration of occlusion as a powerful predictor of 
success but are tempered by two larger eviews (23,41) that did 
not find this variable significant. Interpretation of these data 
remains encumbered by a lack of uniformity and clarity in 
defining duration of occlusion and thus by a lack of clearly 
defined categories. As shown in Table 4, the likelihood of 
success is highly related to a duration of occlusion <3 months 
(p < 0.0003). 
Functional versus absolute occlusions. Several investigators 
have reported increased success if the total occlusion was 
functional rather than absolute (Table 5). A functional occlu- 
sion demonstrates vidence of contrast material beyond the 
area of obstruction in an anterograde manner but fails to 
opacify the entire coronary bed distal to the obstruction (TIMI 
flow grade 1). In an early study of 49 patients, Serruys et al. 
(30) reported that the success rate for patients with a func- 
tional occlusion was 81% and 45% for those with an absolute 
occlusion. Several larger studies (23,24) supported these con- 
clusions, whereas others (36,42) reported similar trends that 
did not reach statistical significance. The aggregate evidence 
indicates a highly significant association between anterograde 
flow and procedural success (p < 0.0001). 
Tapering morphology at point of occlusion. Many morpho- 
logic variables have been reviewed in an attempt o help 
predict success or failure of the procedure. A tapered as 
opposed to an abrupt morphology at the point of coronary 
occlusion has been shown by several investigators (38,41,42) to 
predict a favorable angioplasty procedure outcome (Table 6). 
These investigators reported success rates with a tapered 
morphology of 68% to 88% (p < 0.0001 to p = 0.01) versus 
43% to 59% if the occlusion was abrupt (p < 0.001 to p -- 
0.001). Although Kereiakes et al. (27) did not find this variable 
to be significant, when the studies were combined the overall 
difference was highly significant (p = 0.0001). 
Bridging collateral vessels. Bridging collateral vessels are 
well developed vaso vasorum thought o be unique to chronic 
total occlusions. They angiographically "bridge" the coronary 
vessel proximal to the occlusion, with the patent distal vessel 
allowing anterograde opacification of the distal coronary bed. 
Their development appears to be proportional to the duration 
of occlusion. The presence of bridging collateral vessels is a 
strong predictor of procedural failure (p < 0.001 in aggregate) 
(Table 6) (38,41,42). 
Variables common to all coronary stenoses. Side branch at 
point of occlusion. Although only three studies (38,41,42) 
report that the presence of a side branch at the point of 
occlusion is a predictor of procedural failure, all have reported 
a higher success rate in the absence of a side branch (p < 0.001 
in aggregate). 
Lesion length. Several studies have suggested that the 
length of the occlusion is an important predictor of procedural 
success (Table 7). It was first reported in 1985 (28) that 
procedural success was improved if the length of the nonvisu- 
alized segment of coronary artery distal to the point of 
occlusion was < 1.5 cm. Although individual studies have been 
Table 6. Predictors of Success 
Tapered Morphology 
Study* Present Absent 
Bridging Collateral Vessels Side Branch 
Present Absent Present Absent 
Stone et al. (41) 59/67 22,/37 
Maiello et al. (42) 108/131 119/234 
Tan ct al. (38) 121/176 38/88 
Total 288/374 179/359 
77c~ 50% 
95% CI 73-81c~ 45-55% 
2/11 79/93 15/'24 66/80 
9/31 224/334 107/175 131/190 
10/'51 149/213 76,/143 84/121 
21/93 452/640 198/'342 291/391 
23% 71% 58% 72% 
14 -31% 67-74% 53- 63 % 67-76% 
*Numbers in parentheses are reference numbers. CI = confidence interval. 
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Table 7. Predictors of Success: Other Descriptors 
Lesion Length (cm) Vessel Dilated Extent of Disease 
Study* < 1.5 > 1.5 LAD LCx RCA SVD MVD 
Kcrciakcs ct al. (27) 14/18 19/45 19/32 4/12 16,/30 
Serruys et al. (3(I) 19/30 3/7 5/8 
DiSciascio et al. (35) 13/20 I/3 13/21 
Stone et al. (41) 36/43 137/237 25/34 24/27 27/38 22/26 59/78 
Warren el al. (34) 13/24 6/11 7/9 
lvanhoe t al. (24) 156/204 78/114 98/162 272/382 60/98 
Maiello et al. (42) I 13/1 b0 123/205 1(/7/157 52/73 90/135 103/146 131/219 
Tan et al. (38) 100/152 52/94 86/115 104/197 
Total 263/373 227/393 352/501 168/247 256/403 483/669 354/592 
71'~ 58% 70% 68% 64% 72% 60% 
95% CI 66-75c} 53-63% 66 74% 62-74% 59-68% 69-76% 56-64% 
Numbers in parentheses are reference numbers. CI confidence interval; LAD (LCx. RCA) left anterior descending (left circumflex, right) coronary artery; 
MVD (SVD) multi- (single-)vessel disease. 
contradictory, in aggregate the success rate appears to be 
higher with shorter lengths of occlusion. 
Other descriptors. The dilated coronary artery had not been 
shown to be predictive of success or failure by several investi- 
gators until Ivanhoe et al. (24) reported that angioplasty of a 
chronic total occlusion in the right coronary artery was an 
independent predictor of failure (p = 0.016); this finding was 
validated by Stewart et al. (3), Moliterno et al. (23) and 
DiSciascio et al. (35). However, the confidence limits for the 
aggregate data overlap, making this finding less solid. Location 
of the occlusion was not found to be a predictor of success or 
failure in other reports (23,41). In contrast, the extent of 
disease has been shown in several studies to be an important 
predictor of success or failure. 
Haine et al. (14) reported that unstable symptoms (p < 
0.025) and shorter symptom duration (p < 0.025) were signif- 
icant predictors of procedural success. Ruocco et al. (20) 
reported that the absence of calcium in the lesion was a 
predictor of success, whereas Tan et al. (38) reported that 
larger vessel size was a predictor of success. In the study by Tan 
et al., vessels >3 mm in diameter had a procedural success rate 
of 73%, whereas those <3 mm in diameter had a success rate 
of 48% (p < 0.0001). Unfortunately, other reports did not 
evaluate these variables. 
Reasons for procedural failure. In the early analysis of 
angioplasty of chronic total occlusions, inability to cross the 
lesion with a guide wire was the reason for failure in >75% of 
unsuccessful attempts (34,43). Despite improved procedural 
success ince the early 1980s, this remains the cause of failure 
in >75% of cases (25,34). Less common causes of failure 
include abrupt reocclusion and an inability to either cross the 
lesion with a dilation catheter or dilate the lesion despite a 
successful crossing. In early studies with small numbers of 
patients (31,35,36), these reasons for failure occurred with 
similar frequency. Several small reports (25,34) had no proce- 
dures that failed as a result of acute reocclusion, whereas 17 of 
112 failures in one study were thought o have occurred as a 
result of inability to cross or dilate the lesion with a balloon 
catheter. 
Major complications. Complications or angioplasty of a 
total occlusion are uncommon, perhaps because abrupt closure 
in most cases simply returns the vessel to its previous tate. 
Angiographically visible collateral vessels to the distal segment 
of the totally occluded coronary artery have been reported (6) 
to be present in 80% of chronic occlusions and may exert a 
protective ffect. However, a finite risk of significant compli- 
cations does exist, and this risk may lie somewhere between 
that of diagnostic oronary angiography and that of angioplasty 
of nonoccluded coronary arteries (6). Several studies (14,20) 
have found similar complication rates between angioplasty of 
total occlusions and subtotally occluded coronary arteries. In a 
large study by Haine et al. (14), a major complication was 
reported in 17 (3%) of 500 attempted procedures (Q wave 
myocardial infarction 1%, emergency bypass surgery 1%, 
death 2%). Only two patients with a left main coronary artery 
dissection died of a direct procedural complication. In most 
previous tudies (6), the need for emergency bypass surgery 
ranged from 0% to 4% and was judged to be average 1%. A 
more commonly reported complication has been non-Q wave 
myocardial infarction documented by elevations in creatinine 
kinase. This has been reported (6,14) on average in 2% to 3% 
of procedural attempts (range 0% to 18%), although cardiac 
enzyme levels have not generally been systematically deter- 
mined. 
Long.term outcomes. Conventional balloon angioplasty of 
high grade stenoses enjoys a high procedural success rate but is 
plagued by substantial restenosis rates of up to 40%. Angio- 
plasty of chronic occlusions is similarly plagued by restenosis 
(Table 8). Despite an early report of a modest 20% restenosis 
rate, a range of 40% to 59% has been most commonly found, 
with some investigators reporting a restenosis rate as high as 
65% to 77% (24,25,29,30,34,35,37,44). The point estimate for 
restenosis  53%. In general, angiographic follow-up has been 
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Table 8. Restenosis After Successful Angioplasty ofChronic 
Total Occlusions 
Angiographic 
No. of Follow-Up Restcnosis 
Study* Year Lesions (~) (%) 
Holmes et al. (36) 1984 24 92 33 
Kereiakes et al. (27) 1985 76 30 75 
Serruys et al. (30) 1985 49 71 40 
Melchior et al. (31) 1987 100 71 58 
Finci et al. (28) 1990 2/11) 62 45 
Hamm et al. (37) 1990 154 46 52 
Warren et al. (34) 1990 44 96 65 
lvanhoe eI al. (24) 1992 480 53 54 
Bell et al. (25) 1992 354 29 59 
Total 1,481 53 53 
95% CI 49 57% 
*Numbers in parentheses are reference numbers. CI - confidence interval. 
poor, and angiograms are often performed only when 
prompted by recurrent symptoms. 
Several interesting trends have been observed in patients 
with restenosis. Although restenosis i high, the rate of reoc- 
clusion appears to be low. Second, few of the reocclusions 
result in a clinical infarction (34,37,44). This lack of reocclu- 
sion provides an opportunity for the clinician to supplement 
the angioplasty procedure with medical therapy to reduce 
ischemia relative to the preangioplasty situation of no perfu- 
sion. Last, a dynamic process of restenosis has been observed 
in the cohort of patients tudied by Ellis et al. (44), where 
restenosis at 6, 12 and 24 months was 41%, 66% and 77% 
respectively. The few studies that have reviewed predictors of 
restenosis have had inadequate power to detect significant 
differences. As in angioplasty of subtotal occlusions, several 
investigators (21,34,44) have reported a direct relation be- 
tween postangioplasty lumen diameter and restenosis. Ellis et 
al. (44) reported that coronary angioplasty of the left anterior 
descending or right coronary artery was an independent pre- 
dictor of restenosis (p = 0.04). Others (35) have suggested that 
shorter duration of occlusion may portend a higher risk of 
restenosis. 
Saphenous vein grafts. Some of the studies previously 
discussed (23,25,30,36,37,41,45) included patients who were 
undergoing coronary angioplasty of totally occluded saphenous 
vein bypass grafts, but this group accounted for <3.5% of the 
pooled patient population. The results reported id not sepa- 
rately analyze patients with bypass grafts. Whether the paucity 
of information represents a natural selection bias of operators 
or simply a lack of reporting and investigational interest, or 
both, is unclear. In a study by deFeyter et al. (45) of 2,679 
patients undergoing coronary angioplasty between September 
1980 and December 1988 at the ThoraxCenter in Rotterdam, 
96 underwent coronary angioplasty of a saphenous vein bypass 
graft. Fifteen of these grafts were occluded. Initial success was 
reported in only 4 (27%) of the 15 patients, although 2 of these 
4 had angiographically proved early reocclusion, and a third 
had a reinfarction i the territory of the graft. Thus, only 1 of 
15 patients achieved both initial and long-term success. Em- 
bolization with subsequent myocardial necrosis was reported in 
6 of the 15 patients. These results contrast starkly with results 
reported by Kahn et al. (46) who performed successful coro- 
nary angioplasty in69 (83%) of 82 totally occluded saphenous 
vein grafts. No patients required emergency bypass urgery; 
only 1 died in-hospital, and 2 had a Q wave myocardial 
infarction. Despite 1- and 3-year survival rates of 94% and 81% 
in this patient cohort, only 33% were free of repeat angioplasty 
or coronary artery bypass graft surgery. In an interesting study 
by Hartmann et al. (47), 46 patients with 47 occluded saphe- 
nous vein bypass grafts were pretreated with intracoronary 
urokinase. Recanalization of the bypass graft occurred in 37 
(79%) of the 47 attempts, with 35 of the 37 recanalized vessels 
requiring adjunctive balloon angioplasty. High rates of resten- 
osis, complications and adverse vents were reported uring 
the follow-up period. 
Margolis et al. (48) described the "blush phenomenon," 
markedly delayed flow after contrast injection in a patent 
saphenous vein bypass graft and myocardial staining persisting 
->5 rain in 9 of 29 patients undergoing coronary angioplasty of 
31 totally occluded vein grafts. In five of these nine patients, 
cardiac enzymes were elevated, and a sixth died within a few 
hours after the procedure. Autopsy studies of this patient 
demonstrated diffuse embolization of grumous material, in- 
cluding cholesterol crystals, platelets and fibrin. 
From this limited experience it is obvious that there is 
significant variation in success with balloon coronary angio- 
plasty both alone and in combination with intracoronary 
thrombolytie therapy. However, what is consistent is a signifi- 
cant complication rate often associated with intracoronary 
thromboembolism. Clinical restenosis and long-term cardiac 
events appear to be high compared with those for native vessel 
angioplasty. 
Pharmacologic Therapy 
It is recognized that vascular injury followed by thrombus 
formation, atherosclerotic plaque growth and, eventually, or- 
ganized fibrotic occlusion are responsible for chronic total 
occlusions; this finding provides the rationale for attempting to
treat these lesions with antithrombotic therapy (49). The 
majoriW of failures to treat chronic total occlusions result from 
an inability to maneuver the guide wire through the occlusion, 
making the use of a thrombolytic agent o lyse a passage or 
channel through the occlusion appealing (20). Prolonged 
thrombolytic infusions have become increasingly common 
despite a published experience limited to case reports and 
single-center observational reports in the treatment ofchronic 
total occlusions. Although this treatment strategy has been 
used mainly in saphenous vein graft occlusions, ithas also been 
used in native coronary vessels. Although acute coronary 
occlusions associated with acute myocardial infarctions re- 
spond readily to rapid administration f thrombolytic agents, 
the nature of chronic total occlusions, particularly in saphe- 
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nous vein grafts, allows the responsible thrombus to become 
well organized and fibrotic through the cross-linking of fibrin 
strands and the assimilation of other proteins into the clot 
matrix; this process makes it less likely to rapidly lyse with 
standard thrombolytic infusions (50,51). 
Hartmann et al. (52) first reported using prolonged uro- 
kinase infusions to lyse total saphenous vein graft occlusions as 
a prelude to balloon angioplasty. More recently, this same 
group has described treating 46 consecutive patients (with 47 
total occlusions) with prolonged urokinase infusions (47). By 
infusing 100,000 U/h (range 0.72 to 0.79 million U total dose) 
through the guide catheter and an SOS wire placed several 
centimeters into the occlusion for a mean duration of 31 h, 
they were able to achieve TIMI grade flow 2 or 3 in 37 
occluded grafts (79%). Balloon angioplasty was then success- 
fully performed in 35 of the grafts. Fifteen patients experi- 
enced significant complications, including six with distal em- 
bolization and 10 with large access-site hematomas. At a mean 
follow-up of 27 months, 20 patients undem'ent repeat cardiac 
catheterization. Thirteen of these patients had patent saphe- 
nous vein grafts. 
Experience with prolonged thrombolytic nfusions in native 
artery chronic occlusions is even more limited than that with 
saphenous vein grafts, probably as a result of a reluctance to 
leave a guide catheter in a native coronary artery for a 
prolonged period. Ruocco et al. (53) have reported their 
experience in treating 17 patients with native total occlusions 
(11 right, 3 left anterior descending and 3 circumflex coronary 
arteries). They treated these occlusions with an intracoronary 
infusion of low dose tissue-type plasminogen activator (t-PAl, 
either 18.5 mg over 90 min or 25 mg over 6(1 min, achieving at 
least partial flow in 13 patients, and performed a subse- 
quent successful balloon angioplasty in 16 patients. Despite no 
change in baseline fibrinogen levels, four patients had gingival 
bleeding, and three had significant groin hematomas. Two 
patients had distal embolization, one requiring additional t-PA 
for resolution. 
Although the reported experience is limited, prolonged 
thrombolytic nfusion is an option for the treatment ofchronic 
total occlusions, particularly for occluded saphenous vein 
grafts. Hartmann et al. (47) observationally identified several 
factors that correlate with successful treatment of saphenous 
vein graft occlusions, including a more recent occlusion, an 
anatomic ostial stub to allow favorable guide catheter place- 
ment, patient acceptance and the patient's ability to undergo a
prolonged period of immobility. The complications of the 
procedure include the usual risks of thrombolytic therapy, 
particularly bleeding at the access ite, distal embolization and 
myocardial infarction, guide catheter t auma to the aortocoro- 
nary ostium and marked patient discomfort. 
Very little data exist concerning the long term results of 
these successful prolonged thrombolytic infusions. There are 
no reasons to suppose that the restenosis rate will be any lower 
than that for standard balloon angioplasty, and there are some 
theoretic reasons to think that the risk of reocclusion may bc 
even higher because thrombin activity is increased after throm- 
bolytic administration and may act as a potent stimulus to 
reocclusion and restenosis (54-58). Heparin and aspirin are 
important in minimizing the ischemic omplications of routine 
angioplasty and should be used with thrombolytic therapy 
when treating patients with chronic occlusions (59). 
A number of new antiplatelet and antithrombin agents are 
under development that may be beneficial as adjunctive ther- 
apy to thrombolysis n these situations to facilitate recanaliza- 
tion, to prevent reocclusion and to lessen restenosis. Novel 
antithrombin agents include hirudin (60,61), hirulog (62-64), 
recombinant activated protein C (65), tissue factor pathway 
inhibitor (66), recombinant tick anticoagulant peptide (67) and 
other factor X inhibitors (68). New antiplatelet agents of 
interest include monoclonal antibodies directed against he 
platelet glycoprotein IIb/IIIa receptor, small peptides (which 
contain the arginine-glycine aspartic acid sequence and inhibit 
the platelet IIb/IIIa receptor) and inhibitors of the thrombox- 
ane-A 2 receptor (69-73). Whether these new antithrombotic 
agents will prove useful in the management of patients with 
chronic total occlusions awaits further investigation. 
New Devices 
Intensive research and development have been devoted to 
the design and study of new devices to treat total occlusions. 
These devices can be divided into two categories: The first 
includes devices that are designed to facilitate recanalization 
or otherwise replace conventional guide wires in the primary 
crossing of the total occlusion; the second epends on success- 
ful recanalization with a guide wire and is aimed at improving 
the results of the procedure or reducing complications, or 
both. 
Mechanical approaches to recanalization have taken sev- 
eral innovative forms. The Magnum-Meier guide wire system 
(Schncidcr, Inc.) includes an olive-shaped tip -1 mm in 
cross-sectional diameter coupled to an 0.021-cm stiff guide 
wire (and optional support catheter) (74). This system purport- 
edly improves the angiographer's ability to maintain the tip of 
the wire in an intraluminal position. It has been found (74) to 
be useful in straight, short, tapered occlusions but does not 
work as well in long, diffuse, tortuous or angulated morphol- 
ogies. A different approach is represented bythe Rotacs device 
(Oscor Medical Corp.). This implement consists of a motor- 
ized catheter that ends in a smooth 1.3-ram blunt tip. The 
device is rotated slowly (100 to 200 rpm) to "persuade" a 
channel through the total occlusion. A randomized trial com- 
paring the Rotacs with conventional systems howed no par- 
ticular benefit when the Rotacs device was used first; however, 
a small proportion of patients (<5%) underwent recanaliza- 
tion with the Rotacs when their lesions could not be crossed 
with conventional guide wires, suggesting that his device might 
be useful in reserve (75). To date, only one prospective 
randomized trial has compared these mechanical approaches 
(conventional guide wires, the Magnum-Meier system, and 
Rotacs angioplasty). The highest primary success rate (65.5%) 
was achieved with conventional guide wires followed by a 
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39.9% primary success rate with thc Magnum-Meier system 
and a 30.0% primary success rate with the Rotacs device (76). 
Finally, the most aggressive approach to recanalization f the 
total occlusion is embodied in the Prima Total Occlusion 
Device (Spectranetics, Colorado Springs). This device consists 
of an 0.018-in. hypotube with a distal guide wire containing 
optical fibers for the transmission of 308-mm xenon chloride 
laser energy to the point of contact. Under fluoroscopic 
guidance, the laser wire is activated and advanced across the 
lesion, ablating tissue in its path and recanalizing the lesion. 
This device was successful in crossing five of eight lesions that 
could not be crossed with conventional guide wires {77). Both 
the Rotacs system and the Prima Total Occlusion Devicc 
remain investigational tthis time, and further efinement will 
be needed to improve their clinical potential. 
No specific devices have been developed solely for the 
treatment of the total occlusion (crossed with a guide wire) to 
the exclusion of other indications. Of the new interventional 
devices, excimer laser, directional atherectomy and high speed 
rotational atherectomy have all been used to try to debulk the 
plaque mass and thus create amore faw~rable channel (78,80). 
Results with the excimer laser suggest hat the extent of 
stenosis reduction issimilar to that achieved in lesions that arc 
not totally occluded, with a success rate >90% and a major 
complication rate <3% (78). Similar results have bccn 
achieved with high speed rotational atherectomy and direc- 
tional atherectomy (79,80). The proviso that must be remcm- 
bered with all of these approaches is that the lesion must first 
be crossed with a guide wire, Of the new technologies, ablative 
devices may thus find a primary niche in treating total occlu- 
sions that cannot be crossed with a balloon after successful 
crossing with a guide wire. The true incremental benefit of an 
advanced technology over a conventional balloon remain to bc 
determined. 
Conclusions 
Management of the patient with a chronic total coronary 
occlusion remains a challenge. It is clear that total occlusion 
portends a worse prognosis than a patent vessel in patients 
with an acute myocardial infarction. Observational data have 
suggested that a poor long-term survival might also be ex- 
pected in patients identified to have a chronic total coronary 
occlusion, but adequate prospective or randomized ata are 
lacking. Regardless of its effect on survival, revascularization s 
often required for relief of angina pectoris refractory to 
medical therapy. 
Despite many technologic advances in the past 10 years, 
coronary angioplasty is plagued by generally low procedural 
success and extensive restenosis {although reocclusion is lim- 
ited). The most common obstacle to successful angioplasty 
continues to be recanalization of the occlusion with a guide 
wire. Several clinical and morphologic variables may be useful 
in guiding the use of angioplasty in this patient population. 
These variables include the duration of occlusion, presence of 
bridging collateral vessels and an abrupt (as opposed to 
tapered) lesion morphology, which appear to be inversely 
related to procedural success. Other variables that affect 
angioplasW success of high grade stenoses also need to be 
considered. Complications, although generally less frequent 
than angioplasty of nonoccluded vessels, can be life threaten- 
ing. When angioplasty is successful and uncomplicated, pa- 
tients can expect relief of angina pectoris and a low rate of 
subsequent coronary artery bypass graft surgery. 
Adjunctive pharmacotherapy is being studied for its role in 
recanalizing totally occluded vessels because mechanical de- 
vices have been somewhat disappointing. Future investigations 
will need to focus on the impact on survival and need for 
subsequent coronary artery bypass graft surgery in patients 
referred for coronary angioplasty. The approach to angioplasty 
and role of new devices and local and systemic pharmacother- 
apy need to be investigated further. 
We thank Joseph Greenfield, MD, FACC, for support and guidance; Mary 
Phillips for diligence in the preparation of the manuscript; Laura Gardner for 
statistical advice; and Penny Hodgson for editorial expertise. 
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